A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David S. Hong, Rona Yaeger, Yasutoshi Kuboki, Toshiki Masuishi, Minal A. Barve, Gerald Steven Falchook, Ramaswamy Govindan, Davendra Sohal, Pashtoon Murtaza Kasi, Timothy F. Burns, Corey J. Langer, Sonam Puri, Emily Chan, Pegah Jafarinasabian, Gataree Ngarmchamnanrith, Marko Rehn, Qui Tran, David R. Gandara, John H. Strickler, Marwan Fakih
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Aichi Cancer Center Hospital, Mary Crowley Cancer Research Center, HealthONE, Washington University in St. Louis, University of Cincinnati, University of Iowa Hospitals and Clinics, University of Pittsburgh Medical Center, University of Pennsylvania, Huntsman Cancer Institute, Amgen (United States), UC Davis Comprehensive Cancer Center, Duke University, Duke Medical Center, City Of Hope National Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Amgen
OpenAlex ID: W4206579972